small cap stocks « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘small cap stocks’

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:14 AM on Thursday, November 12th, 2020

Kontrol BioCloud a Safe Space Technology™

Received UL standards approval for its BioCloud® technology
As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

Field Certification was provided by ESAFE

Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, small cap, small cap stocks, stocks, tsx, UL standards approval
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

MedX Health $MDX.ca to Present at the Fall Investor Summit on November 17th $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 7:31 AM on Thursday, November 12th, 2020

Will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18.
To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com/.

NEW YORK, NY / November 12, 2020 / MedX Health Corp. (“MedX”, or the “Company”) (TSXV:MDX), a Company focused on becoming the leader in teledermatology, will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18. To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com/.

During the presentation, MedX’s CEO, Robert von der Porten, and Mike Druhan, President, Dermatology Products & Services, will provide an overview of the Company’s fully integrated telemedicine platform specializing in dermatology and how its platform is being deployed to revolutionize skin cancer detection methods.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

ABOUT MEDX:

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

ABOUT THE INVESTOR SUMMIT:

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To request complimentary investor registration, please visit our website at www.investorsummitgroup.com

News compliments of ACCESSWIRE

FOR MORE INFORMATION:

Please contact Brittney Blocker at [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

SOURCE: MedX Health Corp.

Tags: DermSecure, MedX, MoleMate, Simsys, Skin Cancer, small cap stocks, stocks, telehealth, tsx
Posted in MedX Health Corporation | Comments Off on MedX Health $MDX.ca to Present at the Fall Investor Summit on November 17th $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Empower Clinics $CBDT.ca Announces Closing of $1.228 Million Private Placement Financing and Insider Subscription $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 3:59 PM on Monday, November 9th, 2020

Closed its previously announced private placement of units of the Company, which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit for aggregate gross proceeds of $1,228,356.55
The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner

VANCOUVER, BC / November 9, 2020 / Empower Clinics Inc. (“Empower” or the “Company“) (CSE:CBDT), is pleased to announce that it has closed its previously announced private placement of units of the Company (the “Units“), which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit (the “Offering Price“) for aggregate gross proceeds of $1,228,356.55 (the “Offering“). The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“).

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“), with each Warrant exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.

The Company is also pleased to announce that Steven McAuley, the Chief Executive Officer a director of the Company, participated in the Offering by subscribing for 1,200,000 Units for $60,000.

The Company intends to use the net proceeds raised under the Offering to support the objective of clinic growth, lab testing services, sales and marketing, for general working capital purposes.

In connection with the Offering, the Agent received an aggregate cash fee of $88,000. In addition, the Company granted the Agent compensation options (the “Compensation Options“) exercisable for 1,760,000 Units at an exercise price equal to the Offering Price for a period of 24 months following the closing of the Offering.

The subscription by Mr. McAuley is deemed, “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation requirements of MI 61-101 since none of the securities of the Company are listed on a stock exchange specified in section 5.5(b) thereof. The transaction is exempt from the minority shareholder approval requirements of MI 61-101 since, at the time the transaction was agreed to, neither the fair market value of the transaction nor the fair market value of the consideration for the transaction, insofar as it involves interested parties, exceeded 25% of the Company’s market capitalization.

The securities issued pursuant to the Offering will be subject to a four-month hold period under applicable securities laws in Canada.

In connection with the Offering, $18,356.55 of the subscription funds are a result of a settlement with an arm’s length service provider of through the issuance of 367,131 Units.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with an expanded suite of physician-based services. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability and will lead our diagnostic and scientific advancement.

ON BEHALF OF THE BOARD OF DIRECTORS

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE: Empower Clinics Inc.

Tags: covid19, CSE, Diagnos Inc, Dosed Movie, Dosed Wellness, Hemp, investments, Kai Medical Laboratory, small cap, small cap stocks, stocks
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Closing of $1.228 Million Private Placement Financing and Insider Subscription $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives CSA Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 1:54 PM on Thursday, November 5th, 2020

Kontrol BioCloud® a Safe Space Technology™ –

Announced that it has received CSA standards approval for its BioCloud® technology
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol
CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety

TORONTO, ON / ACCESSWIRE / November 5, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

Field Certification was provided by ESAFE

CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety. The field evaluation process follows the CSA’s SPE-1000 standard, which has three mandatory and non-destructive tests. Upon successful inspection, ESAFE validates the equipment meets CSA’s SPE-1000 standards and labels it approved. ESAFE’s labels are recognized across Canada under the Standards Council of Canada accreditation program.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com.

Image: https://www.accesswire.com/users/newswire/images//10252018KNR2.png

Image: https://www.accesswire.com/users/newswire/images//10252018KNR3.png

Image: https://www.accesswire.com/users/newswire/images//10252018KNR4.png

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud® Analyzer are subject to the risk that the Kontrol BioCloud® Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

SOURCE: Kontrol Energy Corp.

Tags: .CSA, BioCloud, COVID-19, CSA Standards, CSE, energy conservation, google nest, small cap, small cap stocks, stocks, tsx
Posted in All Recent Posts, Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives CSA Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Nickel Explorer Seeks to Bring New Life to Two Former Timmins Mines SPONSOR: Tartisan Nickel $TN.ca $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Posted by AGORACOM at 9:59 AM on Thursday, November 5th, 2020

Class 1 Nickel posts a two-million-tonne-plus resource at Alexo-Dundonald Project
Tartisan owns close to 1,700,000 shares of Class 1 Nickel (NICO:CSE) through vending of Tartisan’s Alexo-Kelex nickel asset in 2018

Crushed ore at the Alexo Mine site near Timmins in 2005.

A new nickel sulphide player has fully emerged in the Timmins camp seeking to revive a well-known piece of mining ground.

Class 1 Nickel and Technologies released a very promising new mineral resource estimate for its Alexo-Dundonald Nickel Project, 45 kilometres northeast of the city.

The Toronto-based company reported an updated estimated indicated mineral resource of 1.25 million tonnes with an average grade of 0.99 per cent of nickel, and a total estimated inferred mineral resource of 1.01 million tonnes with an average grade of 1.08 per cent.

The indicated resource count has jumped 119 per cent since the last mineral estimate in June. The inferred resource ballooned by 1,400 per cent.

The company thinks it has a turn-key project on its hands that can be fast-tracked into nickel and cobalt production with little capital expenditure.

With nickel, cobalt, copper, and platinum group elements in the ground, the company has eyes on supplying battery-grade material for the electric vehicle and stainless steel markets. Nickel sulphide is used in electric vehicle battery cathodes.

Class 1, which went public over the summer on the Canadian Securities Exchange, had been quietly assembling a 20-square-kilometre package of properties that hosted two former small-scale nickel mines along some promising exploration ground that follows a large ‘Z’-shaped group of komatiite rocks, known to contain nickel sulphide.

The project property includes two former one-pit and underground mines – the Alexo and Kelex – that ceased operations in 2005 due to low nickel prices, plus the nearby Dundonald property which contains nickel-bearing zones.

Alexo and Kelex were mined for nickel and copper three separate times around the time of the First World War, during the Great Depression and the Second World War, and lastly between 2004 and 2005.

Class 1 said much of the property has never been probed by drilling and modern geophysics. The last drilling program at Alexo-Kelex was done in 2011, and at Dundonald in 2005.

The company’s exploration program of geophysics has been focused on expanding the resource left behind at Alexo and Kelex, and probe the Dundonald property on the way to planning a drill program and eventually releasing a preliminary economic assessment report for a possible mine.

Management is currently out raising $3 million in flow-through shares for exploration.

SOURCE: https://www.northernontariobusiness.com/industry-news/mining/nickel-explorer-seeks-to-bring-new-life-to-two-former-timmins-mines-2847105

Tags: #Battery, #Demand, #ELO, #ElonMusk, #TN, CSE, EloroResources, Kenbridge, nickel, nickel demand, PEA, small cap stocks, Tesla
Posted in All Recent Posts, Tartisan Nickel | Comments Off on Nickel Explorer Seeks to Bring New Life to Two Former Timmins Mines SPONSOR: Tartisan Nickel $TN.ca $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

$NAM.ca Provides #PGM and #Lithium Exploration Update $LIX.ca $LI.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 9:05 AM on Thursday, November 5th, 2020

Chairman and CEO, Harry Barr stated, “In the last week we have delivered over 300 River Valley samples from our core storage facility to Geolabs in Sudbury from which we expect assay results returned in early December. The analytical packages used at the lab will test for rhodium, palladium, platinum, ruthenium and iridium. Additionally, our field team in Manitoba have collected over 80 rock samples to be sent to Saskatchewan Research Council laboratories from our Lithium One Project. A second phase of rock sampling and mapping begins this week.”

November 5, 2020 – Rockport, Canada – New Age Metals Inc. (NAM) (TSXV:NAM ) ; ( OTC:NMTLF ) ; ( FSE:P7J) (“NAM” or the “Company”) NAM is pleased to provide an update on exploration activities for the Company’s two green metal divisions.

Chairman and CEO, Harry Barr stated, “In the last week we have delivered over 300 River Valley samples from our core storage facility to Geolabs in Sudbury from which we expect assay results returned in early December. The analytical packages used at the lab will test for rhodium, palladium, platinum, ruthenium and iridium. Additionally, our field team in Manitoba have collected over 80 rock samples to be sent to Saskatchewan Research Council laboratories from our Lithium One Project. A second phase of rock sampling and mapping begins this week.”

Exploration Update

Click Image To View Full Size

On September 29 the Company announced its plans for the third phase of exploration and development work at the flagship River Valley Palladium Project which includes the initiation of a project wide rhodium evaluation program and the second round of environmental baseline work in 2020. Story Environmental have scheduled the delivery of a final report presenting their work for the end of January 2021. The stated objective of the rhodium evaluation program is to ultimately evaluate the feasibility of including rhodium as a payable metal as part of the River Valley Project’s payable metal suite , that includes palladium, platinum, gold, copper, and nickel. The work in the final quarter of 2020 will focus on assaying historical River Valley samples for rhodium and other metals. This work will require follow-up metallurgical test work to prove rhodium recoverability.

Click Image To View Full Size

The Company’s River Valley core storage facility holds core from over 700 holes (above)

Click Image To View Full Size

Pictured above are field crew members from the Twohearts foundation who collaborated with New Age consultants at our latest field program at Lithium One.

Click Image To View Full Size

Above is a new outcrop exposure of the Silverleaf pegmatite displaying spodumene-lepidolite mineralization and on the right are.

Additional Activities for Q4 2020

Additional activities planned for Q4 regarding River Valley include exploration targeting which will continue to focus on footwall mineralization, though at the Dana South Zone in addition to the Pine Zone-T3 target. The interior of the River Valley Intrusion will also be re-evaluated for the possibility of MT and gravity surveys to aid development of targeting models for reef-type PGM deposits.

Shares for Services

The Company has issued 226,000 common shares at a deemed value of $0.06 per share to Agora Internet Relations Corp. (“AGORACOM”) pursuant to the terms of the March 2020 agreement. The securities issued represent the third payment for services under the terms of the agreement and are subject to a four month plus one day hold period expiring March 5, 2021.

About NAM

New Age Metals is a junior mineral exploration and development company focused on the discovery, exploration and development of green metal projects in North America. The Company has two divisions; a Platinum Group Metals division and a Lithium/Rare Element division. The PGM division includes the 100% owned, multi-million-ounce, district scale River Valley Project, one of North America’s largest undeveloped Platinum Group Metals Projects, situated 100 km from Sudbury, Ontario. The Company has recently completed a Preliminary Economic Assessment on the project and is working towards Prefeasibility. In Alaska the Company owns 100% of the Genesis PGM-Cu-Ni Project in Alaska. The Lithium division is the largest mineral claim holder in the Winnipeg River Pegmatite Field, where the Company is exploring for hard rock lithium and various rare elements such as tantalum and rubidium. Our philosophy is to be a project generator with the objective of optioning our projects with major and junior mining companies through to production. The Company is actively seeking an option/ joint venture partner for its road-accessible Genesis PGM-Cu-Ni project in Alaska and for our Lithium division in Manitoba.

About the River Valley Palladium Project

The details of the updated Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA) were announced in the press release dated August 9, 2019 and are described on NAM’s website. The pit constrained Updated Mineral Resource Estimate formed the basis of the PEA . At a cut-off grade of 0.35 g/t PdEq, the Updated Mineral Resource Estimate contains 2.867 Moz PdEq in the Measured plus Indicated classifications and 1.059 Moz PdEq in the Inferred classification. The PEA is a preliminary report, but it demonstrates that there are potentially positive economics for a large-scale mining open pit operation, with 14 years of Palladium production. Refer to the NAM website (www.newagemetals.com) for details.

Opt-in List

If you have not done so already, we encourage you to sign up on our website ( www.newagemetals.com ) to receive our updated news.

Qualified Person

The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Dr. Bill Stone, P.Geo., a consulting geoscientist for New Age Metals. Dr. Stone is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release.

On behalf of the Board of Directors

“ Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forw ard-looking statements.

Tags: CSE, lithium, palladium, PGM, PGM Demand, Pine Zone, rhodium, small cap stocks, stocks, tsx, tsx-v
Posted in New Age Metals | Comments Off on $NAM.ca Provides #PGM and #Lithium Exploration Update $LIX.ca $LI.ca $WM.ca $PDL.ca $GLEN

How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 5:51 PM on Wednesday, November 4th, 2020

InnoCan Pharma and Tel Aviv University are collaborating to explore the potential for CBD-loaded exosomes (minute extracellular particles that mediate intracellular communication, including via innate and adaptive immune responses)
The group plans to use these loaded exosomes to target and facilitate recovery of COVID-19–damaged lung cells
From a broader perspective, the prospects for harnessing cannabinoids for immune modulation will be more thoroughly explored in a special issue of Cannabis and Cannabinoid Research

By: Liz Scherer

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing).

There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of its modulating inflammatory and other disease-associated clinical indices, including SARS-CoV-2–induced viral load, hyperinflammation, the cytokine storm, and acute respiratory distress syndrome (ARDS).

Long hobbled by regulatory, political, and financial barriers, CBD’s potential ability to knock back COVID-19–related inflammation might just open doors that have been closed for years to CBD researchers.

Why CBD and Why Now?

CBD and the resulting therapeutics have been plagued by a complicated association with recreational cannabis use. It’s been just 2 years since CBD-based therapeutics moved into mainstream medicine — the US Food and Drug Administration (FDA) approved Epidiolex oral solution for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and in August, the FDA approved it for tuberous sclerosis complex.

CBD’s mechanism of action has not been fully elucidated, but on the basis of its role in immune responses — well described in research spanning more than two decades — it’s not surprising that cannabinoid researchers have thrown their hats into the COVID-19 drug development ring.

The anti-inflammatory potential of CBD is substantial and appears to be related to the fact that it shares 20 protein targets common to inflammation-related pathways, Jenny Wilkerson, PhD, research assistant professor at the University of Florida School of Pharmacy, Gainesville, Florida, explained to Medscape Medical News.

Among the various trials that are currently recruiting or are underway is one that is slated for completion this fall. CANDIDATE (Cannabidiol for COVID-19 Patients With Mild-to-Moderate COVID-19) is a randomized, controlled, double-blind study led by Brazilian researchers at the University of Sao Paulo. The study, which began recruitment this past August, enrolled 100 patients, 50 in the active treatment group (who received capsulated CBD 300 mg daily for 14 days plus pharmacologic therapy [antipyretics] and clinical measures) and 50 who received placebo.

Read Full Article: https://www.medscape.com/viewarticle/940265#vp_3

Tags: Axim Biotechnologies, biopharma, Cardiol Therapeutics Inc, CBD, COVID-19, CSE, CURE Pharmaceutical Holding Corp, InMed Pharmaceuticals Inc., Innocan, MediPharm Labs Corp, small cap, small cap stocks
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on How Cannabis-Based Therapeutics Could Help Fight #COVID Inflammation – SPONSOR: Innocan Pharma $INNO.ca $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

#ACMilan and #Casemiro push the button on new #Esports teams SPONSOR: FansUnite Entertainment $FANS.ca $FUNFF $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 1:50 PM on Wednesday, November 4th, 2020

SPONSOR: FansUnite Entertainment Inc (FANS:CSE) The global online gambling market could potentially hit $1 TRILLION by the end of this decade. FansUnite is well positioned to capitalize on this trend. The company has a full suite of B2B and B2C services and has facilitated over $350M in bets from its 300,000 registered users. The company has also signed with a leading online casino games aggregator to distribute its proprietary Random Number Generated (RNG) games to online casinos and sportsbooks in the European market which will see their RNG games available to over 120 online casino websites. Learn More.

AC Milan and Casemiro push the button on new esports teams

Serie A’s AC Milan has entered the esports with a strategic partnership with Italian organisation QLASH to form a new team that will be called AC Milanm QLASH
The new team will compete in both EA Sports’ FIFA 21 competitions as well as individual and team combat game Brawl Stars
Football links to esports is not just confined to clubs
Brazil and Real Madrid midfielder Carlos Henrique Casemiro has launched an esports team called CaseEsports

November 4 – Serie A’s AC Milan has entered the esports with a strategic partnership with Italian organisation QLASH to form a new team that will be called AC Milanm QLASH.

The new team will compete in both EA Sports’ FIFA 21 competitions as well as individual and team combat game Brawl Stars.

QLASH already has players in both games and AC Milan QLASH will debut at the Brawl Stars World Finals later this month. Paris St Germain, who have expanded their esports activity beyond the football video game platforms, will also be at the Brawl Stars finals.

Casemiro strikes

Football links to esports is not just confined to clubs. Brazil and Real Madrid midfielder Carlos Henrique Casemiro has launched an esports team called CaseEsports.

His team will play on the Counter-Strike: Global Offensive game platform and already has a number of players signed up who will be based in a gaming house in Madrid.

Casimiro has already lined up a number of sponsors for CaseEsports including gaming chair maker Drift, HyperX, Spanish glasses maker Hawkers, and BŮH.

The team will debut officially in the upcoming DreamHack Open qualifiers in December.

Source: http://www.insideworldfootball.com/2020/11/04/ac-milan-casemiro-push-button-new-esports-teams/

Tags: Allied Esports Entertainment Inc, Bragg Gaming Group Inc, CSE, EA sports, eGambling, egaming, Enthusiast Gaming Holdings Inc, esports, Fandom Sports Media Corp, Fortnite, Inc, Jackpot Digital Inc, LOL, Penn National Gaming, poker, Score Media and Gaming Inc, small cap stocks
Posted in All Recent Posts, eSports Investing, FansUnite Entertainment Inc. | Comments Off on #ACMilan and #Casemiro push the button on new #Esports teams SPONSOR: FansUnite Entertainment $FANS.ca $FUNFF $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Empower Clinics $CBDT.ca Growth Strategy Accelerates With Recent Major Initiatives. Updates Status And Outlook Into 2021 $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:23 AM on Monday, November 2nd, 2020

2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:

2019 + 86% To $2.03M
Q4 + 217% To $625,000
Q1 + 416% To $790,000
Q2 + 56% To $923,000

This performance has translated into the following year-to-date in 2020:

Revenue $1.7M vs $745K = 130% Growth
Patient Visits 12,400 vs 5,500 = 125% Growth

VANCOUVER BC / November 2, 2020 / EMPOWER CLINICS INC. Empower Clinics (CBDT:CSE)(EPWCF:OTC)(8EC:FRA) (the “Company” or “Empower“), an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to provide shareholders with a status report on many initiatives announced over the past several weeks for the purposes of providing greater visibility into the Company’s outlook into 2021.

Steven McAuley, CEO of Empower Clinics stated “2020 is the year that established Empower Clinics as a formidable Health & Wellness Company with a solid foundation and great growth prospects. Given the speed at which we have been moving since I took over the leadership reigns in 2019, it is prudent to take a moment to provide our shareholders with both a current snapshot, as well as, our expectations for continued growth into 2021.”

HIGHLIGHTS & UPDATES

2020 Revenue Growth The Company has experienced significant revenue growth over the past year as evidenced by the following results:
- 2019 + 86% To $2.03M
- Q4 + 217% To $625,000
- Q1 + 416% To $790,000
- Q2 + 56% To $923,000

This performance has translated into the following year-to-date in 2020:

Revenue $1.7M vs $745K = 130% Growth
Patient Visits 12,400 vs 5,500 = 125% Growth

Going forward, given the Company’s diversification into telemedicine, COVID-19 testing, medical laboratory testing for enterprise customers, and the proposed clinic expansion into Canada, all of which serves to diversify Empower well beyond our Southwestern U.S. clinic operations, going forward “patient visits” will be just one of many of the Company’s overall KPI’s (Key Performance Indicators).

Kai Medical Laboratory COVID-19 Testing Growth Includes Film & Television Industry Empower completed the closing of the Kai Medical Laboratory acquisition with the signing of the Member Purchase Interest Agreement October 5, 2020 and then subsequently completed the filing of all required regulatory documents with the State of Texas and other regulatory bodies.

The Company is now working through integration and implementing aggressive growth strategies including servicing new COVID-19 testing contracts for the film & television industry and supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

Sun Valley Health COVID-19 Regional Testing Growth Sun Valley Health with the support of Kai Medical Laboratory testing and medical billing capabilities, is expanding its RT-PCR testing with the commencement of drive-up testing for consumers in Mesa, Arizona and within clinic locations. The program allows the Company to provide free COVID-19 testing for consumers with Medicare and Medicaid insurance coverage in Arizona and for consumers who do not have active health insurance coverage in the state.
$1,100,000 Proposed Private Placement The previously announced proposed private placement with Mackie Research Capital Corporation as sole agent and sole bookrunner (the “Agent”) on October 21, 2020 remains on track for closing as planned on or about the week of November 2, 2020.
Canadian Clinic Acquisition The recently announced non-binding term sheet for the acquisition of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health”) is progressing as planned through the final due diligence phase with an anticipated closing in November 2020.
Q3 2020 Financial Statements The Company anticipates filing its third quarter 2020 financial statements and MD&A well in advance of the November 30, 2020 filing deadline. Financial and accounting controls supported by CFO Kyle Appleby enable the Company to maintain high compliance standards.

McAuley went on to say “Our company is rapidly evolving into providing an integrated healthcare experience that spans from testing to treatment by combining cutting edge technologies including telemedicine and state of the art lab testing. Add to this the fact that we are now serving enterprise level clients as promised and partnering on initiatives such as our recently announced travel bubble, it’s safe to say we are on the path to becoming a formidable small cap health & wellness company in 2021. I want to thank our loyal shareholders for trusting my leadership transition, welcome all of our newest shareholders and we look forward to delivering continued accelerated growth in 2021 and well beyond.”

ABOUT EMPOWER:

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley

Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the anticipated date of closing of the Momentum Health acquisition and the occurrence thereof; the expected number of clinics and patients following the proposed closing; the future potential success of Kai Medical Laboratory; the future success of the Sun Valley’s franchise model; the completion of the private placement, date of closing or the occurrence of a closing; the impact if any of COVID-19 testing by Sun Valley Health and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: covid19, CSE, Diagnos Inc, Dosed Movie, Dosed Wellness, Hemp, investments, Kai Medical Laboratory, small cap, small cap stocks, stocks
Posted in All Recent Posts, Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca Growth Strategy Accelerates With Recent Major Initiatives. Updates Status And Outlook Into 2021 $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Iconic $ICM.ca Receives Core Drilling Geochemistry for Bonnie Claire #Lithium Project, Nevada $NRM.ca $CYP.ca $LI.ca $ALB $LAC.ca

Posted by AGORACOM-JC at 3:08 PM on Friday, October 30th, 2020

Received geochemical results for sediments from two core holes at the Bonnie Claire Lithium Deposit in Nevada
Both drill holes contain intercepts of +1,000 ppm lithium and continue to show that results are consistent with those from prior drilling
Core hole BC2001C intersected 67 meters (220 feet) averaging 1209 ppm Li and contained a high of 1710 ppm Li. Core hole BC2002C contained a high of 1070 ppm Li

Vancouver, British Columbia–(October 30, 2020) – Iconic Minerals Ltd. (TSXV: ICM) (OTC Pink: BVTEF) (FSE: YQGB) (“Company” or “Iconic”) is pleased to announce that it has received geochemical results for sediments from two core holes at the Bonnie Claire Lithium Deposit in Nevada. Both drill holes contain intercepts of +1,000 ppm lithium and continue to show that results are consistent with those from prior drilling. Sediment geochemical analysis was done by ALS Chemex of Reno, Nevada.

Core hole BC2001C intersected 67 meters (220 feet) averaging 1209 ppm Li and contained a high of 1710 ppm Li. Core hole BC2002C contained a high of 1070 ppm Li. Occasional lighter colored sediments seen in the core may indicate some leaching of soluble elements is occurring. Water samples, highly diluted by added drill water, were taken from each core hole. The water samples were analyzed for dissolved lithium by Western Environmental Testing of Sparks, Nevada. Of the four samples taken the high for dissolved lithium was 38 ppm. The highest water sample taken in all of Iconic’s previous drilling at Bonnie Claire, with the exception of one non-repeatable sample, was 4.1 ppm Li. As a result of these encouraging results the water sampling was also taken in the RC drilling program. These samples were taken at rod changes after clearing the hole of drill water.

The RC (reverse circulation) drilling has now been completed. A total of four holes ranging from 61 to 109 meters (200 to 358 feet) were drilled to expand the resource and collect samples for metallurgy. Samples have been sent for testing to ALS Chemex of Reno Nevada for assaying. The drilling extended the current resource approximately 2,500 meters (8,200 feet) to the south.

The Bonnie Claire Lithium Property Characteristics:

The Property is located within Sarcobatus Valley that is approximately 30 km (19 miles) long and 20 km (12 miles) wide. Quartz-rich volcanic tuffs, that contain anomalous amounts of lithium, occur within and adjacent to the valley. Geochemical analysis of the local salt flats has yielded lithium values up to 340 ppm. The gravity low within the valley is 20 km (12 miles) long, and the current estimates of depth to basement rocks range from 600 to 1,200 meters (2,000 to 4,000 feet). The current claim block covers an area of 35 km2 (13.5 mi2) with potential to be underlain by lithium-rich sediments.

Richard Kern, Certified Professional Geologist (#11494) and CEO of Iconic is the Qualified Person who has prepared and reviewed this press release in accordance with NI 43-101 reporting standards.

On behalf of the Board of Directors

SIGNED: “Richard Kern“
Richard Kern, President and CEO

Contact:
Keturah Nathe
VP Corporate Development
(604) 336-8614

For further information on ICM, please visit our website at www.iconicminerals.com.

The Company’s public documents may be accessed at www.sedar.com.

Tags: Bonnie Claire Deposit, clean energy, CSE, Electric Vehicles, EV, green energy, lithium, small cap stocks, stocks
Posted in Iconic Minerals | Comments Off on Iconic $ICM.ca Receives Core Drilling Geochemistry for Bonnie Claire #Lithium Project, Nevada $NRM.ca $CYP.ca $LI.ca $ALB $LAC.ca

Posts Tagged ‘small cap stocks’

Why CBD and Why Now?

AC Milan and Casemiro push the button on new esports teams

Categories